Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > Novel selective IL-23 blocker equally effective in patients with metabolic syndrome

Novel selective IL-23 blocker equally effective in patients with metabolic syndrome

Presented By
Dr Alice Gottlieb, Tufts University School of Medicine, USA
Conference
EADV 2019
Trial
reSURFACE 1 and 2
Two post-hoc analyses of data from the reSURFACE 1 and 2 studies compared the efficacy of tildrakizumab in people with and without metabolic syndrome. Surprisingly, no difference was observed in efficacy between these groups [1,2]. Obesity and metabolic syndrome are common comorbidities in patients with moderate-to-severe psoriasis. The adipose tissue is a complex organ that secretes several adipokines, involved in the regulation of several metabolic processes. The unbalanced production of pro- and anti-inflammatory adipokines in obesity contributes to the development of a chronic low-grade inflammation state, which seems to favour worsening of psoriasis lesions and a poorer response to treatment [3]. Previous data has shown that obese patients often show a reduced response to therapy [4]. The metabolic syndrome can also have a negative impact on long-term drug survival of biologic treatment [5]. Tildrakizumab is a selective IL-23 blocker for therap...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on